In a matter of months, mRNA-1273 by Moderna was the first COVID-19 vaccine to enter clinical trials in the U.S. The mRNA-1273 sequence encodes for the pre-fusion form of S protein, a SARS-CoV-2 surface protein that binds to host angiotensin-converting enzyme receptors, leading to viral fusion and entry into host cells. This evidence concerns the gene PROS1 and COVID-19.